DE60332538D1 - Oligosaccharid-biomarker für mucopolysaccharidosen und andere verwandte störungen - Google Patents

Oligosaccharid-biomarker für mucopolysaccharidosen und andere verwandte störungen

Info

Publication number
DE60332538D1
DE60332538D1 DE60332538T DE60332538T DE60332538D1 DE 60332538 D1 DE60332538 D1 DE 60332538D1 DE 60332538 T DE60332538 T DE 60332538T DE 60332538 T DE60332538 T DE 60332538T DE 60332538 D1 DE60332538 D1 DE 60332538D1
Authority
DE
Germany
Prior art keywords
mps
oligosaccharide
target
solution
mucopolysaccharidoses
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60332538T
Other languages
English (en)
Inventor
Peter John Meikle
Maria Fuller
Steve Lewis Ramsey
Enzo Ranieri
John Joseph Hopwood
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Womens and Childrens Hospital Adelaide
Original Assignee
Womens and Childrens Hospital Adelaide
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Womens and Childrens Hospital Adelaide filed Critical Womens and Childrens Hospital Adelaide
Application granted granted Critical
Publication of DE60332538D1 publication Critical patent/DE60332538D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/66Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood sugars, e.g. galactose
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G01N2400/10Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • G01N2400/38Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence, e.g. gluco- or galactomannans, Konjac gum, Locust bean gum or Guar gum
    • G01N2400/40Glycosaminoglycans, i.e. GAG or mucopolysaccharides, e.g. chondroitin sulfate, dermatan sulfate, hyaluronic acid, heparin, heparan sulfate, and related sulfated polysaccharides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Diabetes (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Saccharide Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE60332538T 2002-06-14 2003-06-13 Oligosaccharid-biomarker für mucopolysaccharidosen und andere verwandte störungen Expired - Lifetime DE60332538D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPS2930A AUPS293002A0 (en) 2002-06-14 2002-06-14 Identification of oligosaccharides and their use in the diagnosis and evaluation of mucopolysaccharidoses and other related disorders
PCT/AU2003/000731 WO2003106997A1 (en) 2002-06-14 2003-06-13 Oligosaccharide biomarkers for mucopolysaccharidoses and other related disorders

Publications (1)

Publication Number Publication Date
DE60332538D1 true DE60332538D1 (de) 2010-06-24

Family

ID=3836492

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60332538T Expired - Lifetime DE60332538D1 (de) 2002-06-14 2003-06-13 Oligosaccharid-biomarker für mucopolysaccharidosen und andere verwandte störungen

Country Status (11)

Country Link
US (1) US20060286034A1 (de)
EP (2) EP1532438B1 (de)
JP (1) JP2005530157A (de)
AT (1) ATE467834T1 (de)
AU (2) AUPS293002A0 (de)
CA (1) CA2488811A1 (de)
DE (1) DE60332538D1 (de)
NO (1) NO20050186L (de)
NZ (1) NZ537512A (de)
TW (1) TW200400351A (de)
WO (1) WO2003106997A1 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4498918B2 (ja) 2002-04-30 2010-07-07 生化学工業株式会社 リソソーム病の検出方法
US8173443B2 (en) 2003-03-31 2012-05-08 Women's And Children's Hospital Multiplex screening for lysosomal storage disorders (LSDs)
JPWO2005050191A1 (ja) * 2003-10-27 2007-11-29 宏 葛西 酸化的損傷グアニン化合物とこれの濃度補正物質の同時分析方法及びこの分析方法に用いる分析装置
JP2006047239A (ja) * 2004-08-09 2006-02-16 National Institute Of Advanced Industrial & Technology 硫酸化単糖の同定方法及び硫酸化単糖異性体混合物の分析方法
JP4965999B2 (ja) * 2005-12-27 2012-07-04 セント ルイス ユニバーシティ ムコ多糖症の診断方法
WO2009091994A2 (en) 2008-01-18 2009-07-23 Biomarin Pharmaceutical Inc. Manufacture of active highly phosphorylated human lysosomal sulfatase enzymes and uses thereof
JP2009229426A (ja) * 2008-03-25 2009-10-08 Sumitomo Bakelite Co Ltd 糖鎖分析法
CA2726111C (en) * 2008-07-23 2015-01-27 P Devices Inc. Portable plasma based diagnostic apparatus and diagnostic method
US8592140B2 (en) 2009-01-02 2013-11-26 Biomarin Pharmaceutical Inc. Detection of oligosaccharides
US9029530B2 (en) 2009-01-02 2015-05-12 Biomarin Pharmaceutical Inc. Detection of oligosaccharides
US8232073B2 (en) 2009-01-02 2012-07-31 Zacharon Pharmaceuticals, Inc. Quantification of non-reducing end glycan residual compounds
US8809009B2 (en) 2009-01-02 2014-08-19 Biomarin Pharmaceutical Inc. Methods of diagnosing a disease and methods of monitoring treatment of a disease by quantifying a non-reducing end glycan residual compound and comparing to a second biomarker
EP2776553B1 (de) * 2011-11-07 2018-07-11 Shire Human Genetic Therapies, Inc. Biomarker für das sanfilippo-syndrom und anwendungen davon
US9982288B2 (en) * 2014-04-30 2018-05-29 The Nemours Foundation Mucopolysaccharidosis IVA/VII screening and treatment method
MA40954A (fr) * 2014-11-14 2017-09-19 Shire Human Genetic Therapies Détermination de niveaux de glycosaminoglycane par spectrométrie de masse
CN107941963A (zh) * 2017-12-29 2018-04-20 珍奥集团股份有限公司 一种增加骨密度保健食品中盐酸氨基葡萄糖与硫酸软骨素的含量测定方法
CN116124971A (zh) * 2018-08-07 2023-05-16 江苏双林海洋生物药业有限公司 农产品中氨基葡萄糖含量的检测方法
CN108872441B (zh) * 2018-08-14 2021-09-03 江苏康缘药业股份有限公司 一种测定氨基葡萄糖和硫酸软骨素的方法
CN109781997A (zh) * 2019-01-22 2019-05-21 中国人民解放军总医院 用于诊断粘多糖病ⅱ型的生物标志物及其应用
CN114264741B (zh) * 2021-12-15 2022-08-19 山东大学 一种鉴别猪来源肝素是否掺反刍类动物肝素的方法
IT202200007808A1 (it) 2022-04-20 2023-10-20 Luigi Michele Pavone Composizioni terapeutiche per malattie causate da accumulo di eparan solfato
CN115032377B (zh) * 2022-08-11 2022-11-01 裕菁科技(上海)有限公司 一种粘多糖贮积症生物标记物及应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5310646A (en) * 1988-05-13 1994-05-10 Regents Of The University Of Minnesota Method for the detection of mucopolysaccharide storage diseases
US5310464A (en) 1991-01-04 1994-05-10 Redepenning Jody G Electrocrystallization of strongly adherent brushite coatings on prosthetic alloys
US6506384B1 (en) * 1997-12-31 2003-01-14 New York University Early detection of mycobacterial disease
NZ337946A (en) * 1998-09-25 2001-11-30 Tokyo Gas Co Ltd C-13 labelled oligosaccharides and polysaccharides useful as diagnostic agents for pancreatic exocrine function
RU2196988C2 (ru) * 2000-04-19 2003-01-20 Государственный новосибирский областной клинический диагностический центр Способ диагностики мукополисахаридозов
MXPA02012032A (es) * 2000-06-07 2003-04-25 Univ Duke Metodos de diagnostico de la enfermedad de pompe y otras enfermedades por almacenamiento de glucogeno.
GB0128498D0 (en) * 2001-11-28 2002-01-23 Inst Of Child Health International standards for sphingolipids

Also Published As

Publication number Publication date
EP1532438A1 (de) 2005-05-25
ATE467834T1 (de) 2010-05-15
EP1532438A4 (de) 2006-12-06
JP2005530157A (ja) 2005-10-06
NO20050186L (no) 2005-03-10
EP1532438B1 (de) 2010-05-12
AU2003233255C1 (en) 2009-07-16
CA2488811A1 (en) 2003-12-24
AUPS293002A0 (en) 2002-07-04
WO2003106997A1 (en) 2003-12-24
AU2003233255A1 (en) 2003-12-31
EP2081023A2 (de) 2009-07-22
EP2081023A3 (de) 2009-10-07
NZ537512A (en) 2006-09-29
AU2003233255B2 (en) 2009-02-19
NO20050186D0 (no) 2005-01-13
US20060286034A1 (en) 2006-12-21
TW200400351A (en) 2004-01-01

Similar Documents

Publication Publication Date Title
NO20050186L (no) Oligosakkaridbiomarkorer for mucopolysakkaridoser og andre beslektede forstyrrelser
JP6947721B2 (ja) 非アルコール性脂肪性肝炎を診断及び評価するための方法
Banne et al. Reduced level of serum thiols in patients with a diagnosis of active disease
US20090011452A1 (en) Method of Prognosis of Mental Diseases, E.G. Autism and Cerebral Palsy
HK1208467A1 (en) Methods for the diagnosis of dementia and other neurological disorders
DE69905310D1 (de) Reflexalgorithmus zur frühen und kostengünstigen Diagnose von myokardischen Infarkten geeignet für automatisierte diagnostische Plattformen
KR20150052311A (ko) Ft-icr-ms/ms를 이용한 치은염 및 치주염의 바이오마커에 대한 타액 프로테옴의 분석
RU2008103988A (ru) Способ диагностики рассеяного склероза
WO2004046729A3 (en) Bodily fluid markers of tissue hypoxia
Strohmaier et al. Spot urine samples for the metabolic evaluation of urolithiasis patients
ATE242484T1 (de) Verfahren zur untersuchung von nierenkrankheiten
DE60232595D1 (de) Methode zur diagnose von nierenerkrankungen
ATE314648T1 (de) Diagnostisches verfahren für asthma
JP2009537797A (ja) 神経変性疾患の診断及び早期診断のためのinvitro方法
JP2020064055A (ja) 脂肪性肝疾患の検出又はリスクの予測方法、脂肪性肝疾患を検出するための診断薬キット及びバイオマーカー、対象の肝線維化の進行度の判定方法、並びに対象の肝線維化の進行度を判定するためのバイオマーカー
Tharwat The cardiac biomarker troponin I and other haematological and biochemical variables in downer camels (Camelus dromedarius)
JP2020034538A (ja) 脂肪性肝疾患の検出又はリスクの予測方法、脂肪性肝疾患を検出するための診断薬キット及びバイオマーカー、対象の肝線維化の進行度の判定方法、並びに対象の肝線維化の進行度を判定するためのバイオマーカー
WO2010005077A1 (ja) パーキンソン病の疾患関連たんぱく質およびその使用
JP6592627B1 (ja) Nafld又はnashの検出又はリスクの予測方法、nafld又はnashを検出するための診断薬キット、対象における肝線維化の進行度の判定方法、及び対象における肝線維化の進行度を判定するための診断薬キット
DE102008022609B4 (de) Verfahren zum Nachweis des Vorkommens von Nierensteinen und/oder Entzündungen der ableitenden Harnwege
ATE237276T1 (de) Automatisches diagnosesystem zur durchführung von immunoassays und klinisch-chemischen assays nach einem reflexalgorithmus
ATE352037T1 (de) Immunochromatographiesystem und verfahren zur gleichzeitigen identifikation von aga-und t-tg- antikörpern und verwendung dafür zur diagnose der zöliakiekrankheit
Ho et al. Percutaneous bone biopsy in the diagnosis of renal osteodystrophy
BR0209681A (pt) Método e kit para o diagnóstico in vivo ou para o monitoramento de uma doença que envolve uma reação inflamatória dentro de um paciente
JP6592637B1 (ja) Nafld又はnashの検出又はリスクの予測方法、nafld又はnashを検出するための診断薬キット、対象における肝線維化の進行度の判定方法、及び対象における肝線維化の進行度を判定するための診断薬キット

Legal Events

Date Code Title Description
8364 No opposition during term of opposition